Evidence map›Paper›PMID 35275549›Full record

SynthesisJournal of Alzheimer's disease : JAD2022

Safety and Efficacy of Monoclonal Antibodies for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Published and Unpublished Clinical Trials.

Eleonora Lacorte, Antonio Ancidoni, Valerio Zaccaria, Giulia Remoli, Leonardo Tariciotti, Guido Bellomo, Francesco Sciancalepore, Massimo Corbo, Flavia L Lombardo, Ilaria Bacigalupo and 3 more

Open access · bronzeAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of Alzheimer's disease : JAD, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 8 pooled it
10.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 8 syntheses or guidelines pooled it, 95 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Eleonora LacorteNational Center for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome, Italy.
Antonio AncidoniNational Center for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome, Italy.
Valerio ZaccariaDepartment of Human Neuroscience, Sapienza University, Rome, Italy.
Giulia RemoliNational Center for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome, Italy.
Leonardo TariciottiNeurosurgery Department, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.
Guido BellomoNational Center for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome, Italy.
Francesco SciancaleporeNational Center for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome, Italy.
Massimo CorboDepartment of Neurorehabilitation Sciences, Casa Cura Policlinico, Milan, Italy.
Flavia L LombardoNational Center for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome, Italy.
Ilaria BacigalupoNational Center for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome, Italy.
Marco CanevelliNational Center for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome, Italy.
Paola PiscopoDepartment of Neuroscience, Italian National Institute of Health, Rome, Italy.
Nicola VanacoreNational Center for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome, Italy.
Istituto Superiore di Sanità · ITFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITSapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMonoclonal antibodies (mAbs) are currently among the most investigated targets for potential disease-modifying therapies in Alzheimer's disease (AD).

objectiveOur objectives were to identify all registered trials investigating mAbs in MCI due to AD or AD at any stage, retrieve available published and unpublished data from all registered trials, and analyze data on safety and efficacy outcomes.

methodsA systematic search of all registered trials on ClinicalTrials.gov and EUCT was performed. Available results were searched on both platforms and on PubMed, ISI Web of Knowledge, and The Cochrane Library.

resultsOverall, 101 studies were identified on 27 mAbs. Results were available for 50 trials investigating 12 mAbs. For 18 trials, data were available from both published and unpublished sources, for 21 trials only from published sources, and for 11 trials only from unpublished sources. Meta-analyses of amyloid-related imaging abnormalities (ARIA) events showed overall risk ratios of 10.65 for ARIA-E and of 1.75 for ARIA-H. The meta-analysis of PET-SUVR showed an overall significant effect of mAbs in reducing amyloid (SMD -0.88), but when considering clinical efficacy, data on CDR-SB showed that treated patients had a statistically significant but clinically non-relevant lower worsening (MD -0.15).

conclusionOur results suggest that the risk-benefit profile of mAbs remains unclear. Research should focus on clarifying the effect of amyloid on cognitive decline, providing data on treatment response rate, and accounting for minimal clinically important difference. Research on mAbs should also investigate the possible long-term impact of ARIA events, including potential factors predicting their onset.

Indexed as

Alzheimer DiseaseAmyloidosisCognitive DysfunctionAmyloidAmyloidogenic ProteinsAntibodies, MonoclonalHumansAmyloidAmyloidogenic ProteinsAntibodies, MonoclonalAlzheimer’s diseaseamyloidmeta-analysismild cognitive impairmentmonoclonal antibodiessafetysystematic reviewtreatment outcome

Identifiers

PMID35275549
PMCPMC9198746
OpenAlexW4221002324

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.